We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-1.26%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.91B
AUM Growth
-$2.56B
Cap. Flow
+$5.6B
Cap. Flow %
70.85%
Top 10 Hldgs %
34.65%
Holding
156
New
13
Increased
15
Reduced
59
Closed
23

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$7.7B
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$114M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$76.7M
4
FOLD
Amicus Therapeutics
FOLD
+$76.6M
5
SCPH
scPharmaceuticals
SCPH
+$48.1M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$172M
2
AET
Aetna Inc
AET
+$163M
3
BIIB icon
Biogen
BIIB
+$128M
4
MRK icon
Merck
MRK
+$108M
5
GILD icon
Gilead Sciences
GILD
+$107M

Sector Composition

Rank Sector Weight
1 Healthcare 91.1%
2 Financials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRAY
26
DELISTED
ViewRay, Inc.
VRAY
$87.6M 1.11%
9,458,567
– –
GBT
27
DELISTED
Global Blood Therapeutics, Inc.
GBT
$84.9M 1.07%
2,157,730
-235,905
-10% -$8.81M
JUNO
28
DELISTED
Juno Therapeutics, Inc.
JUNO
$83.9M 1.06%
1,835,188
-206,420
-10% -$10.3M
MGLN
29
DELISTED
Magellan Health Services, Inc.
MGLN
$82.6M 1.05%
855,843
-26,757
-3% -$2.37M
JAZZ icon
30
Jazz Pharmaceuticals
JAZZ
$16.1B
$81.9M 1.04%
607,900
-141,300
-19% -$19.6M
AET
31
DELISTED
Aetna Inc
AET
$80.7M 1.02%
447,552
-948,948
-68% -$163M
FOLD
32
DELISTED
Amicus Therapeutics
FOLD
$80.2M 1.01%
+5,572,500
New +$76.6M
AERI
33
DELISTED
Aerie Pharmaceuticals
AERI
$79.4M 1%
1,329,600
-108,582
-8% -$6.58M
LOXO
34
DELISTED
Loxo Oncology, Inc
LOXO
$79.2M 1%
94,100,036
+92,372,036
+5,346% +$7.7B
VTRS icon
35
Viatris
VTRS
$20.9B
$77.6M 0.98%
1,834,300
-1,766,800
-49% -$67.5M
TMO icon
36
Thermo Fisher Scientific
TMO
$215B
$73.9M 0.94%
389,400
-144,800
-27% -$27.7M
ILMN icon
37
Illumina
ILMN
$29.1B
$71.8M 0.91%
337,698
-71,960
-18% -$14.8M
BLUE
38
DELISTED
bluebird bio
BLUE
$68.4M 0.87%
29,648
-7,558
-20% -$15.3M
IRWD icon
39
Ironwood Pharmaceuticals
IRWD
$596M
$67.8M 0.86%
5,403,089
-1,473,396
-21% -$19.2M
JNJ icon
40
Johnson & Johnson
JNJ
$646B
$65M 0.82%
465,300
-659,100
-59% -$91.8M
NVRO
41
DELISTED
NEVRO CORP.
NVRO
$62M 0.78%
897,791
+402,891
+81% +$32.2M
ISRG icon
42
Intuitive Surgical
ISRG
$128B
$56.1M 0.71%
460,800
-46,800
-9% -$5.86M
CRVS icon
43
Corvus Pharmaceuticals
CRVS
$1.1B
$55.7M 0.7%
5,379,349
– –
PVLA
44
Palvella Therapeutics
PVLA
$2B
$54.8M 0.69%
90,745
– –
ASMB icon
45
Assembly Biosciences
ASMB
$497M
$54.2M 0.69%
99,836
+37,500
+60% +$17M
UNH icon
46
UnitedHealth
UNH
$387B
$52.8M 0.67%
239,500
-140,500
-37% -$29.8M
INSY
47
DELISTED
Insys Therapeutics, Inc.
INSY
$52M 0.66%
5,406,844
-764,596
-12% -$5M
AGN
48
DELISTED
Allergan plc
AGN
$47M 0.59%
287,290
-86,300
-23% -$15.5M
INSM icon
49
Insmed
INSM
$22.5B
$46.7M 0.59%
1,496,791
-378,225
-20% -$11.2M
LKFT
50
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$45.7M 0.58%
486,990
-36,800
-7% -$3.48M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2017 Portfolio in Review

As of Q4 2017, OrbiMed held 156 positions worth $7.91B, down 24% from $10.5B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed deployed $5.6B of net new capital in Q4 2017, opening 13 new positions and adding to 15 existing holdings. Its largest new stake was Rhythm Pharmaceuticals: 2,901,295 shares worth $43.5M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Aetna Inc, an estimated $163M trimmed.

  • OrbiMed's largest Q4 2017 buy was Rhythm Pharmaceuticals: 2,901,295 shares worth $43.5M.
  • OrbiMed added most to Loxo Oncology, Inc in Q4 2017, an estimated $7.7B increase.
  • OrbiMed's biggest Q4 2017 reduction was Aetna Inc, cutting an estimated $163M.
  • OrbiMed fully exited Incyte in Q4 2017, selling an estimated $172M.
  • OrbiMed's ten largest holdings make up 35% of its $7.91B portfolio in Q4 2017.
  • OrbiMed opened 13 new positions and closed 23 in Q4 2017.
  • OrbiMed's portfolio value fell 24% quarter-over-quarter to $7.91B.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.